Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The mutated version of the virus exhibited resistance to the antiviral drug remdesivir.

Remdesivir-Linked Covid-19 Mutation Found In Immunocompromised Patient

SHANGHAI, Nov. 10, 2021 /PRNewswire/ -- Everest Medicines and Gilead Sciences, Inc. (Nasdaq: GILD) jointly announces today that Everest Medicines' (HKEX 1952.HK) Phase 2b EVER-132-001 study of sacituzumab govitecan (marketed as Trodelvy® in the United States) met its primary endpoint of overall response rate (ORR) in metastatic triple-negative breast cancer (TNBC). EVER-132-001 is a single-arm, multi-center Phase 2b registrational study evaluating sacituzumab govitecan in 80 patients enrolled in China for the treatment of adults with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one for metastatic disease.

Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new clinical and real-world data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place from November 12-15. Presentations include the impact of treatment with bulevirtide, an investigational treatment for people with chronic hepatitis delta virus (HDV) in the U.S. that is conditionally approved in Europe, real-world data on global efforts

Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting®

Amgen

Biogen

Incyte

Regeneron Pharmaceuticals

Biotech stocks have been picking up steam lately and several positive catalysts could keep the wind at the industry's back. Here are five names analysts are bullish on right now.

5 Buy-Rated Biotech Stocks to Bolster Your Portfolio

VanEck Vectors Biotech ETF

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

How Are Biotech ETFs Reacting to These Q3 Earnings Releases?

A blowout third quarter did little to ignite the shares of Gilead Sciences Inc. ( GILD , Financial) as investors seemed to be spooked by concerns over the staying power of the company's antiviral drug for Covid-19 and a decline in its core business.

Big Quarter for Gilead's Covid Drug Fails to Boost Stock

FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that data at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (December 11-14) will showcase continued leadership across both approved and investigational CAR T-cell therapies and medicines. Gilead and Kite will present more than 20 abstracts, including a plenary presentation and six oral presentations, across several hematolo

Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline

Gilead Is A Solidly Profitable, High Dividend-Yielding Stock

AbbVie

Bristol-Myers

Merck

Takeda Pharmaceutical

For years, one of the most dependable sectors, especially for more conservative investors, was health care, which included the top pharmaceutical and biotech stocks among other holdings.

5 Big Dividend Biotech and Pharmaceutical Stocks Have Strong Upside Potential

Gilead Sciences Inc. GILD, -2.63% said sales of its COVID-19 treatment Veklury soared during the third quarter, driven by the need to treat people hospitalized with COVID-19 during this summer's surge in the U.S.

Sales of Gilead's COVID-19 drug jumped in conjunction with the surge in delta cases this summer

Gilead (GILD) beats on sales and earnings in the third quarter. While the HIV business is affected by the pandemic and generics, Veklury maintains momentum.

Gilead (GILD) Q3 Earnings Beat on Increased Veklury Sales

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from the ongoing, multinational, observational single-arm, non-comparative real-world cohort BICSTaR study, which is designed to evaluate the antiviral effectiveness and safety profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in 1,135 people living with HIV. The BICSTaR study also collected patient-reported outcomes in routine clini

Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting

Gilead Sciences Inc (NASDAQ: GILD) posted higher-than-expected Q3 earnings on strong demand for its COVID-19 antiviral treatment. Adjusted EPS increased 26% Y/Y to $2.65, beating the consensus of $1.74.

Gilead Trims Non-COVID Product Sales Outlook, Though Q3 Earnings Beat Street Estimates

Gilead Sciences, Inc.'s (GILD) CEO Daniel O'Day on Q3 2021 Results - Earnings Call Transcript

On Thursday, Gilead Sciences Inc. (NASDAQ:GILD) shares edged lower by 2.3% in the after-hours session despite posting solid fiscal Q3 results. The company announced its most recent quarterly results after markets closed, beating analyst expectations on revenue and earnings.

Should you invest in Gilead Sciences after guiding FY2021 earnings above estimates?

Gilead Sciences Inc. shares slipped in the extended session Thursday even as the biotech drug maker reported quarterly results that topped Wall Street estimates and hiked its outlook for the year.

Gilead Sciences stock dips as results, outlook top Street view

Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earnings as strong demand for its COVID-19 antiviral treatment, Veklury, offset flagging sales of its HIV drugs.

Gilead beats profit expectations on COVID-19 drug sales

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada) to evaluate the efficacy of Gilead's Trop-2 targeting antibody-drug conjugate Trodelvy® (sacituzumab govitecan-hziy) in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as a first-line treatment for patients with locally advanced or metastatic trip

Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2021. “This was a very strong third quarter with continued positive momentum for both our commercial performance and our pipeline progress,” said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. “Veklury is making a significant impact as the COVID-19 pandemic continues to evolve. The dynamics of the HIV treatment market further improved a

Gilead Sciences Announces Third Quarter 2021 Financial Results

As volatility increases, investors tend to shift their focus to strong dividend payers to help them weather the storm.

Cure Your Income Deficiency With These 3 Healthcare Dividend Gems

Fidelity MSCI Health Care ETF

iShares U.S. Healthcare ETF

Johnson & Johnson

Eli Lilly

Pfizer

UnitedHealth Group

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.

Healthcare ETFs in Focus as Q3 Earnings Unfold

Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement.

Gilead Sciences Earnings Preview

It's much too early to count these companies out.

2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays

FOSTER CITY, Calif. & KENILWORTH, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the start of a Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy. “Partnerships and collaborations are critical to continuing the tremendous progress

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) third-quarter 2021 results.

News for Gilead Sciences Stock (GILD)